(MENAFN) US drug maker, Pfizer Inc. confirmed it had decided not to separate into traded companies by separating its low-growth generics from its patent-protected branded medicines.
Instead, Chief Executive, Ian Read, stated the company was already accessing many of the potential benefits of a split while retaining the operational strength, efficiency and financial flexibility of operating as a single company.
Chief Financial Officer Frank D"Amelio said: "Over time, any potential gap between Pfizer"s market valuation and an implied Sum of the Parts (SOTP) market valuation has closed."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.